Detect Parkinson using gut biopsy
- Trial ID
- NCT05347407
- Official Title
- Biochemical Characterization of Parkinson's Disease-related Proteins in the Enteric Nervous System as a Proxy for Pathological Changes in the Brain
- Goal
- Detect Parkinson using gut biopsy
- Status
- RECRUITING
- Sponsor
- Weill Medical College of Cornell University
- Study Type
- OBSERVATIONAL
- Enrollment
- 60 participants
- Conditions
- Parkinson Disease
- Interventions
- Colonoscopy
Plain-Language Summary
Goal: to find out whether abnormal Parkinson's-related proteins in the gut, especially misfolded alpha-synuclein, mirror the pathological changes in the brain and could serve as a peripheral marker of disease. Approach: during a colonoscopy researchers take small biopsies of the enteric nervous system and run biochemical tests to detect misfolded alpha-synuclein and related protein changes, the study is observational so no new drug is given. Eligibility: adults 45 to 75 years old with Parkinson's disease or at higher risk (for example REM sleep behavior disorder or a first degree relative), Hoehn and Yahr stage 1 to 4, able to undergo colonoscopy and give informed consent; people with other non-synuclein neurodegenerative diseases, active GI disease, inability to safely stop anticoagulants, pregnancy, recent substance abuse, or serious uncontrolled medical problems are excluded.
Locations
- Weill Cornell Medicine, New York, New York, United States
Frequently Asked Questions
- What is this trial testing?
- This trial is studying Colonoscopy. Goal: to find out whether abnormal Parkinson's-related proteins in the gut, especially misfolded alpha-synuclein, mirror the pathological changes in the brain and could serve as a peripheral marker of disease. Approach: during a colonoscopy researchers take small biopsies of the enteric nervous system and run biochemical tests to detect misfolded alpha-synuclein and related protein changes, the study is observational so no new drug is given. Eligibility: adults 45 to 75 years old with Parkinson's disease or at higher risk (for example REM sleep behavior disorder or a first degree relative), Hoehn and Yahr stage 1 to 4, able to undergo colonoscopy and give informed consent; people with other non-synuclein neurodegenerative diseases, active GI disease, inability to safely stop anticoagulants, pregnancy, recent substance abuse, or serious uncontrolled medical problems are excluded.
- Who can participate?
- Participants must be between 45 Years and 75 Years.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This trial is estimated to last approximately 5 years and 4 months.